The mesalamine market is anticipated to grow from USD 236.39 million in 2025 to USD 338.41 million by 2034, with a compound annual growth rate (CAGR) of 4.14% during the forecast period from 2025 to 2034.
Mesalamine Market Key Highlights
- U.S. tariff shifts in 2025 may cause volatility in global Mesalamine trade and supply chains.
- Mesalamine (5-ASA) is widely used for ulcerative colitis and Crohn’s disease.
- Rising IBD prevalence worldwide is a key market growth driver.
- Ulcerative colitis remains the largest therapeutic application.
- Top 3 players (Syntese A/S, PharmaZell, Cambrex) hold over 50% share.
- Europe dominates the market share, followed by Asia-Pacific and North America.
- Over 60% of global production is concentrated in Europe and the U.S.
Mesalamine Market Segmentations
By Type
- Purity ≥ 97%
- Purity ≥ 98%
- Purity ≥ 99%
By Application
- Tablets
- Capsules
- Granule
- Suppository
- Enema
- Others
By Region
- North America
- U.S.
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait
Tables & Figures
By Type
| Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Purity ≥ 97% | 113.50 | 116.78 | 120.13 | 123.58 | 127.09 | 130.68 | 134.36 | 138.11 | 141.95 | 145.86 | 149.85 |
| Purity ≥ 98% | 68.10 | 71.39 | 74.84 | 78.45 | 82.23 | 86.19 | 90.34 | 94.68 | 99.23 | 103.99 | 108.98 |
| Purity ≥ 99% | 45.40 | 48.23 | 51.21 | 54.35 | 57.67 | 61.17 | 64.86 | 68.75 | 72.85 | 77.18 | 81.74 |
By Application
| Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tablets | 102.15 | 105.18 | 108.33 | 111.53 | 114.81 | 118.17 | 121.62 | 125.15 | 128.75 | 132.44 | 136.23 |
| Capsules | 45.40 | 47.99 | 50.71 | 53.58 | 56.60 | 59.78 | 63.12 | 66.64 | 70.34 | 74.24 | 78.33 |
| Granule | 34.05 | 35.70 | 37.42 | 39.23 | 41.12 | 43.10 | 45.17 | 47.34 | 49.62 | 52.00 | 54.49 |
| Suppository | 18.16 | 18.68 | 19.20 | 19.74 | 20.29 | 20.85 | 21.43 | 22.01 | 22.61 | 23.22 | 23.84 |
| Enema | 18.16 | 18.68 | 19.20 | 19.74 | 20.29 | 20.85 | 21.43 | 22.01 | 22.61 | 23.22 | 23.84 |
| Others | 9.08 | 10.17 | 11.32 | 12.56 | 13.88 | 15.29 | 16.79 | 18.39 | 20.10 | 21.91 | 23.84 |
By Region
| Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | 68.10 | 70.17 | 72.29 | 74.48 | 76.73 | 79.05 | 81.44 | 83.89 | 86.42 | 89.02 | 91.69 |
| Europe | 63.56 | 65.69 | 67.90 | 70.17 | 72.53 | 74.96 | 77.48 | 80.08 | 82.77 | 85.54 | 88.42 |
| Asia-Pacific | 68.10 | 72.05 | 76.20 | 80.57 | 85.14 | 89.95 | 95.01 | 100.32 | 105.89 | 111.75 | 117.89 |
| Latin America | 13.62 | 14.36 | 15.14 | 15.96 | 16.82 | 17.72 | 18.66 | 19.65 | 20.69 | 21.78 | 22.92 |
| Middle East & Africa | 13.62 | 14.13 | 14.65 | 15.20 | 15.77 | 16.36 | 16.97 | 17.60 | 18.26 | 18.94 | 19.65 |
List of Figures & Tables
Frequently Asked Questions
The global Mesalamine market was valued at around US$ 227 million in 2024, with steady growth expected through 2034.
Key drivers include the rising prevalence of inflammatory bowel disease (IBD), particularly ulcerative colitis, growing awareness of treatment options, and increasing healthcare expenditure in emerging economies.
Europe leads with market share, followed by Asia-Pacific and North America.
Major companies include Syntese A/S, PharmaZell, and Cambrex Corporation, which collectively account of the global market.
Challenges include supply chain disruptions, pricing pressures, patent expiries, and regulatory compliance across multiple regions.
Oral formulations dominate the market, though rectal formulations are also widely used for localized treatment.
The market forecast spans 2024 to 2034, with 2024 as the base year.
Companies are focusing on capacity expansion, strategic collaborations, tariff risk mitigation, and regional diversification to sustain competitive advantage.
Make Every Move Strategic. Get Insights, Fully Customized
- On-Demand Metrics & KPIs
- Industry-Specific Dashboards
- Quick Turnaround, No Compromises
Published By
Kesiya Chacko
Reviewed By
Aditi Shivarkar
Reviewed By
Aman Singh
Our Client
Mesalamine Market Size to Capture USD 338.41 Million by 2034
The mesalamine market is projected to expand from USD 227 million in 2024 to USD 338.41 million by 2034, with a CAGR of 4.14%.
